Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotopelabeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.
Introduction
Over the last 25 years, since Kohler and Milstein 1 first described making monoclonal antibodies (MAbs), much time has been spent trying to develop these reagents in order to treat human disease. Until recently, progress has been notoriously slow and by 1994 only one MAb, anti-CD3 (OKT3), had been licensed for clinical use in treating renal and cardiac allograft rejection. In the past 5 years, however, the situation has changed dramatically, with numerous MAbs now having clinical potential, of which seven have been approved for treating human disease. Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based. The first indication that MAbs might have significant therapeutic potential came in the early 1980s, when Nadler and colleagues, 2 soon to be followed by Levy et al 3 reported the first two cases of lymphoma patients experiencing a complete response (CR) to a brief course of treatment with a 'tailormade' mouse anti-idiotype (anti-Id) MAb. This notable success, together with (limited) animal data, sparked widespread academic and commercial interest, followed by a period of extreme enthusiasm in applying Mab-based therapeutic approaches to treat human cancer. 4 It was anticipated that the progress MAbs had brought to biomedical research and clinical diagnostics would be repeated for therapeutics. Unfortunately, this did not materialize: subsequent trials with different types of murine and human-mouse chimeric MAbs in various cancers failed to meet the success of the first anti-Id Mab case. A number of limitations emerged from these studies: 4, 5 (1) dif- ficulties in identifying a completely tumor-specific target; (2) the impracticality of constructing a unique antibody for each patient; (3) the development of an immune response to murine immunoglobulins (human anti-mouse antibodies, HAMA). 6 By the end of the 1980s enthusiasm for therapeutic MAbs was waning; murine native (unconjugated), radioactively labeled or toxin-conjugated MAbs failed to yield significant clinical responses; moreover, they were not uncommonly associated with toxicities, predominantly in the form of serum sickness from repeated administrations as a result of HAMA development, hematological or other toxicity (pulmonary toxicity and encephalopathy). Therefore, refinement of the antibody molecule itself in order to avoid immunogenicity -HAMA by chimerization or 'humanization', optimization of the methodology to obtain more stable radioactively labeled MAbs and better understanding of the biology of antigenic epitopes expressed on developing lymphocytes -the counterparts of lymphoma cells -appeared the major prerequisites to enter into the novel rapidly progressing era of Mab therapy of NHL. The most widely selected target for MAb-based therapeutic modalities in B cell NHL was the CD20 antigen for reasons that will be analyzed in the present report.
The CD20 target
The CD20 antigen is restricted to B cells: 7 its expression starts at the pre-B stage of B cell ontogeny and continues until the immunoblast stage; importantly, CD20 is not expressed on either precursor lymphoid cells or in the vast majority of plasma cells. CD20 antigen expression on malignant B cells corresponds to the ontogenetic stage at which the malignancy is assigned: thus, non-Hodgkin's lymphomas (NHL) are CD20-positive in over 90% of cases, contrasting with B cell acute lymphoblastic leukemia which is positive in about half the cases and neoplastic plasma cells of multiple myeloma which are usually CD20-negative. 8 Although the function of CD20 has not yet been fully unraveled and CD20-knockout mice do not show a prominent phenotype, 9 CD20 does appear to play a role in Ca 2+ transport as cells transfected with CD20 increase their resting levels of intracellular Ca 2+ . [10] [11] [12] Some of the most interesting data on CD20 signalling comes from work showing that when crosslinked with MAb, CD20 is rapidly reorganized in the lipid bilayer membrane. 13 CD20 might be one of many signalling molecules (including the kinases Lyn, Fyn and Lck) able to divide into the sphingolipid and cholesterol-rich microdomains so important in antigen receptor signalling in lymphocytes. 14 Certain characteristics make the CD20 antigen an appealing target for monoclonal antibody therapy; it is present on the surface of mature B cells 8 and has been noted in approxi-mately 93% of patients with B cell lymphoma, 15 but is not present on B cell precursors, mature plasma cells, or other nonlymphoid normal tissues. 8, 15 Additionally, it does not circulate in the plasma as free protein that could competitively inhibit MAb binding to lymphoma cells, does not shed from the surface of CD20 + cells after antibody binding and does not seem to be internalized or, subsequently, downregulated on antibody binding. 16, 17 Crosslinking of CD20 with various Mabs induces a number of signalling events, including increased protein tyrosine phosphorylation, activation of protein kinase C and upregulation of C-MYC. 18 In vitro, these changes can regulate B cell growth and appear to depend upon the association of CD20 with an ill-defined factor that couples it to the Src-kinases Lyn, Fyn and Lck. 19 There is a growing body of evidence confirming that anti-CD20 Mabs are able to recruit immune effector mechanisms, such as complement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC); 17 furthermore, they might also employ other intracellular signalling mechanisms to achieve direct cytotoxic and/or apoptotic effects.
Rituximab: general features
Rituximab (IDEC-C2B8) is a highly specific mouse/human chimeric antibody engineered by grafting the variable regions targeting the CD20 antigen from a murine anti-CD20 antibody (2B8) on to human constant regions. 15 Rituximab has a longer half-life than the parent murine antibody and is less immunogenic, essentially eliciting no HAMA response. 17, 20 The reactivity of Rituximab is restricted to B cells: Rituximab binds complement (C1q) and induces antibody-dependent cellular cytotoxicity: 17, 20 in vitro, follicular lymphoma cell lines are lysed with Rituximab and human complement, albeit with marked heterogeneity in the extent of the response. Rituximab also inhibits cell proliferation and directly induces apoptosis. 21 Furthermore, many data now suggest that Rituximab sensitizes malignant B cells to chemotherapy, mainly through disruption of anti-apoptotic pathways. 22 Thus, synergy with chemotherapeutics is a further mechanism of action of Rituximab.
The crucial part played by complement activation and increased apoptosis in the activity of Rituximab gives some hints as to potential mechanisms responsible for resistance to this agent. Indeed, there is now abundant evidence in favor of a role of complement inhibitors CD55 and CD59 in resistance of lymphoma cells to complement-mediated cytotoxicity (CDC); in both lymphoma cell lines and primary patient (CLL, MCL, prolymphocytic leukemia) tumor cells, blocking antibodies to CD55 and CD59 increased CDC five-to sixfold. 23, 24 Nevertheless, the picture is far from clear: it was recently shown that both the expression of complement inhibitors CD55, CD59 and CD46 on pretreatment lymphoma cells and their in vitro susceptibility to CDC does not predict clinical outcome after Rituximab treatment.
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Rituximab single-agent therapy of lymphoma
The efficacy and safety of Rituximab single-agent therapy has been reported in patients with low-grade or follicular NHL in a number of phase I/II studies. [26] [27] [28] [29] [30] Phase I studies of single doses up to 500 mg/m 2 and multiple-dose schedules of up to 375 mg/m 2 weekly for four doses demonstrated that the anti-CD20 antibody Rituximab was well tolerated with only mild Leukemia to moderate infusion-related toxic effects (fever, chills, asthenia, nausea, rash, and urticaria). In the initial phase I trial, Rituximab produced rapid depletion of circulating B cells that slowly recovered during 3-6 months. Tumor biopsies performed 2 weeks after a single infusion showed antibody bound to tumor cells and a decrease in the percentage of B cells in the tumor. In a multiple-dose study, 375 mg/m 2 was well tolerated and thus selected for further phase II trials. 27, 28 In a seminal paper, McLaughlin et al 31 reported the results of a large multi-institutional trial. In that study, 166 patients with relapsed or refractory low-grade or follicular B cell lymphoma were studied. The overall response rate (RR) in the intent-to-treat analysis was 48% (CRs: 6%): with a median time of follow-up of 11.8 months, the projected median time to progession (TTP) was 12.5 months. A detailed pharmacokinetic analysis performed on a subset of patients revealed that there was a stepwise increase of peak levels and serum halflife after each course. A significant correlation was noted between the number of circulating B cells at baseline and the rapidity of antibody clearance from the systemic circulation after the first infusion. Importantly, only one patient (Ͻ1%) developed human anti-chimeric antibodies (HACA). The results of the above two trials provided the basis for the fast-track approval of Rituximab by the FDA for the treatment of relapsed or refractory indolent lymphoma. Since then, many studies have contributed in better defining the therapeutic role of Rituximab as monotherapy or in combination with standard chemotherapy for management of indolent lymphoma.
In an important recent paper, Colombat et al reported the results of a multi-institutional trial of a 4-dose course of Rituximab in previously untreated follicular lymphoma patients with a low tumor burden (32) . Of the fifty patients enrolled in the study, 36 responded within a month of treatment, with 10 patients in CR, 3 in CR/unconfirmed (CRu) and 23 in PR. During the first year, 1/13 CR/CRu patients and 9/23 PR patients showed disease progression. A noteworthy finding of that study was that a significant proportion of patients initially informative for bcl-2/Ig rearrangement were PCR negative in peripheral blood at month 12; furthermore, a significant association was noted between molecular and clinical responses.
Single agent trials of Rituximab in previously untreated patients with various other subtypes of indolent NHL are currently underway: interim results from these studies again suggest appreciable activity with minimal toxicity. In this context, at the 2001 American Society of Hematology 43rd Annual Meeting, two groups independently reported encouraging results with Rituximab monotherapy in extranodal marginal zone lymphomas of MALT-type. 33, 34 Finally, the activity of single-agent Rituximab was demonstrated in patients with progressed hairy cell leukemia (with 5/10 responders) 35 
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Chronic lymphocytic leukemia CD20 is expressed in almost all patients with chronic lymphocytic leukemia (CLL), albeit with marked heterogeneity as regards antigen density (with most patients exhibiting a low density); 40 thus, Rituximab would be considered to have a place in the treatment of CLL. However, initial studies suggested that Rituximab was less active in small lymphocytic lymphoma (SLL)/CLL and, furthermore, that administration in CLL patients was associated with significant infusion-related toxicity. 31, 38, 41 Two studies have evaluated the activity of higher dose and more intensive treatment with Rituximab in CLL. 42 In the study by O'Brien et al, 43 40 patients with CLL were treated with four weekly doses of Rituximab 375 mg/m 2 for the first infusion, with dose escalation beginning with the second infusion and held constant for each patient; escalated doses were from 500 to 2250 mg/m 2 . The overall RR was 40% with all responses being partial remission; the median time to progression was 8 months There was clear evidence of a dose-response: patients treated at 500 to 825 mg/m 2 had a 22% RR, those treated at 1000-1500 mg/m 2 had a 43% RR and, finally, those treated at the highest dose of 2250 mg/m 2 had a 75% RR. Importantly, severe first-dose toxicity was uncommon.
In the study by Byrd et al, 44 33 patients with CLL were treated on a thrice weekly dosing schedule: an initial dose of 100 mg/m 2 followed by doses of 250 mg/m 2 or 375 mg/m 2 on day 3 and thereafter thrice weekly for 4 weeks. The overall RR was 45% (3% CR, 42% PR) with a median duration of response for the 15 responders of 10 months (range 3-17+). Only one patient discontinued therapy due to severe infusionrelated toxicity; significant infusion-related reactions were seen in 13 patients: they were probably attributed to cytokine release and resolved by the third infusion. Encouraging results were also obtained by Hainsworth et al, 45 even at standard doses albeit with prolonged administration. Thus, with the exception of the German Chronic Lymphocytic Leukemia Group who recently reported low efficacy of single-agent therapy, 46 the results of most studies to date point to the potential utility of Rituximab in the treatment for CLL patients, perhaps as part of combination protocols.
Combination therapy with Rituximab: indolent lymphoma
Combination with chemotherapy
The above studies seem to have succeeded by overcoming two major stumbling blocks: lower CD20 antigen density on CLL cells and shorter half-life of Rituximab in CLL patients (due to the 'antigen sink' effect 42 or mediated by soluble CD20 47 ). Their results prompted trials with combinations of Rituximab with various chemotherapeutic agents, especially fludarabine and cyclophosphamide. The rationale of such trials is that Rituximab has different mechanisms of action and toxicities from chemotherapy and, furthermore, that it can sensitize lymphoma cells to the cytotoxic effects of certain chemotherapeutics. In the 2001 American Society of Hematology 43rd Annual Meeting, Garcia Manero et al 48 reported results with a chemo-immunotherapy regimen consisting of Rituximab, fludarabine and cyclophosphamide on 102 both previously untreated and treated (27/102 fludarabine resistant) CLL patients. With a median follow-up of 13+ months, using NCI criteria the total RR was 72%, with a CR rate of 23%; importantly, there were even 'molecular' remissions, in the sense that 5/13 patients in CR had undetectable clonal Ig rearrangements by PCR.
The combination of Rituximab with CHOP chemotherapy was proven extremely efficacious in a phase II trial in indolent lymphoma conducted by Czuczman et al. 49 In that study, 40 patients (31 previously untreated) with low-grade/follicular lymphoma received a combination of Rituximab with standard CHOP chemotherapy for six courses. On an intent-totreat analysis, the overall RR was 95% (38/40 patients), with 22/40 patients (55%) attaining a CR and 16/40 (40%) a partial response (PR). Interestingly, in some evaluable patients a conversion from PCR positivity to negativity for bcl-2/Ig sequences was identified. Finally, the toxicity profile of the combination was comparable to that of either Rituximab or CHOP alone, while the addition of Rituximab did not compromise CHOP dose intensity.
A multicenter Italian study prospectively evaluated minimal residual disease by PCR for bcl-2/Ig rearrangement after the sequential administration of CHOP and Rituximab in previously untreated follicular lymphoma patients; 50 patients either in CR or in PR after CHOP were eligible for 4 weekly doses of Rituximab if they were persistently PCR positive. At 12 weeks, 35/77 Rituximab-treated patients were PCR negative in the bone marrow and peripheral blood; at the last follow-up (+44 weeks), 25/77 patients were still PCR negative. A durable PCR negative status was associated with superior outcome, as freedom from recurrence at 3 years was 57% compared to 20% in patients never achieving a PCR negative status or reverting again to PCR positive (P Ͻ 0.001).
A number of further studies reported on the application of Rituximab in combination with various multidrug chemotherapy regimens in indolent lymphoma. The German Low Grade Lymphoma Study group (GLSG) conducted a prospective, randomized trial comparing chemotherapy (fludarabine/cyclophosphamide/mitoxantrone, FCM) plus Rituximab to chemotherapy (FCM) alone in patients with relapsed follicular lymphoma. 51 In 43 patients evaluable for response, an overall RR of 95% was observed, which was significantly superior to the overall RR of 68% with FCM alone (P = 0.0007); furthermore, the combined treatment was not associated with additional toxicity compared with standard FCM. Gregory et al 52 used Rituximab as consolidation therapy for patients with untreated advanced low-grade lymphoma who initially received four to six courses of combined fludarabine/mitoxantrone chemotherapy. In 19 patients evaluable for response, an overall RR of 95% was observed with a CR rate of 53%; six patients have been maintained in CR for over 8 months during follow-up, while four have sustained PR for 9 or 10 months. Serious adverse effects and infections were rare. Finally, Czuczman et al 53 recently presented the final results of a phase II single institution trial of Rituximab plus fludarabine in 40 patients with both previously untreated and treated low-grade lymphoma: they reported an overall RR of 90% with a CR/CR-unconfirmed rate of 82.5%, with median duration of response not reached at 15+ (4+ to 36+) months. Although toxicity was deemed acceptable, the use of the combination was associated with significant cytopenia (mostly neutropenia); however, apart from a trend to increased herpes simplex/zoster infections, no other opportunistic infections or increased incidence of bacterial infections were seen.
Combination with other MAbs and biological agents
Combinations of Rituximab with other MAbs targeting alternative lymphocyte antigens are currently under evaluation. Alemtuzumab (CAMPATH-1H) is a MAb binding to the CD52 antigen, which is found on the majority of T and B lymphocytes, as well as other cells of the hematopoietic system, with the exception of CD34 + progenitor cells and granulocytes. Alemtuzumab is currently licensed in the USA for treatment of patients with fludarabine-refractory B-CLL. Two phase I studies have examined the application of combinations of Rituximab + Alemtuzumab in patients with relapsed/refractory B-CLL, 54, 55 and demonstrated the feasibility and safety of the combination associated with encouraging activity in this selected group mainly consisting of poor-risk patients. These prompted a novel phase II study, which aims at further evaluating the clinical efficacy of this regimen. Other combinations being currently explored are anti-CD22 Mab (Epratuzumab) + Rituximab 56 and anti-CD80 MAb + Rituximab 57 for relapsed/refractory NHL.
Rituximab has also been combined with interferon-alpha (IFNa) in low-grade lymphoma. A study by Kimby et al, 58 on behalf of The Nordic Lymphoma Group reported results obtained in 124 evaluable patients with follicular grade 1-2 CD20 + B cell NHL who had received no prior chemotherapy (n = 90) or who had received Ͻ6 months of chlorambucil (n = 34). All patients received weekly Rituximab × 4. Patients who attained CR (11%) received no further therapy, while patients who attained PR/minor response were randomized to receive either another 4 weeks of Rituximab alone or weekly Rituximab together with IFNa.
The RR for IFNa + Rituximab was 94% with 48% CRs, whereas that for continued Rituximab alone was 77% with 22% CRs. This study indicates that the addition of interferon to Rituximab is associated with an increased chance of attaining an objective response, when compared with continued use of Rituximab alone.
Currently, another area of active investigation with rapidly increasing interest is the recognition that tumor-specific T cell responses can be generated against B cell NHL, since the tumor-associated antigen related to the B cell lymphoma immunoglobulin (Ig) sequence, is the Ig idiotype, which can be more efficiently presented on patient's dendritic cells. 59 These vaccination strategies are best suited for consolidative therapy after achieving a major response/debulking with intensive chemotherapy. At this point Rituximab could play a Leukemia pivotal role in such an approach since it can achieve rapid and effective tumor cytoreduction with or without chemotherapy usually leading to a state of minimal residual disease. Moreover, as Rituximab depletes the B cell arm of the immune system, subsequent boost of idiotype-specific T cells might prolong remission duration and probably survival.
Combination therapy with Rituximab: aggressive lymphoma
Over the past 20 years, the CHOP regimen has resulted in clinical responses in over 80% of aggressive lymphoma patients; however, CHOP is curative in less than 40%. Attempts to improve treatment outcome by utilizing more aggressive regimens or increasing CHOP dose intensity have met with no success; 60 thus CHOP has remained the goldstandard therapy for aggressive lymphoma.
The first study to demonstrate the safety and efficacy of Rituximab in combination with CHOP in aggressive lymphoma was reported by Vose et al. 61 In that phase II trial, 33 patients with previously untreated aggressive lymphoma received Rituximab on day 1 of each cycle in combination with six cycles of CHOP chemotherapy on day 3 of each cycle. The overall RR was 94% with 20 patients (61%) attaining a CR. At the time of publication of the results of the trial, with a median follow-up of 26 months, the median duration of response and time to progression had not been reached. Furthermore, the addition of Rituximab to CHOP did not increase toxicity nor did it compromise CHOP delivery.
Between 1998 and March 2000, the Groupe d'Etude des Lymphomes de l'Adulte (GELA) conducted a randomized trial comparing CHOP chemotherapy plus Rituximab to CHOP alone in elderly patients with untreated diffuse large B cell lymphoma. Patients were assigned to receive either eight cycles of CHOP every 21 days (197 patients) or eight cycles of CHOP plus Rituximab administered on day 1 of each cycle (202 patients). The results of this trial were recently published: 62 CR rate was significantly higher in the chemoimmunotherapy grroup (76% vs 63%, P = 0.005); with a median follow-up of 2 years, event-free and overall survival were significantly higher in the combined modality group (P Ͻ 0.001 and P = 0.007, respectively). Importantly, a significant benefit of the combined treatment over CHOP alone was observed both among patients with low risk disease (International Prognostic Index, IPI, 0 or 1, P Ͻ 0.001) and those with high risk disease (IPI 2 or 3, P Ͻ 0.03). The two regimens had comparable toxicity; however, a trend for more herpes zoster infections was observed in the Rituximab plus CHOP group. This seminal study demonstrated the first improvement in overall survival for any regimen compared with CHOP and will very likely establish (at least for elderly patients with aggressive lymphoma) Rituximab as an agent to be combined with standard chemotherapy for front-line treatment. Furthermore, these exciting results triggered the MInT 64 hyper-CVAD in adult Burkitt's lymphoma 65 and CDE (infusional cyclophosphamide, doxorubicin and etoposide) in HIV-associated lymphoma. 66 These initial reports suggest that Rituximab given with various combination chemotherapy regimens is tolerable and associated with satisfactory RRs. Further evaluations of these trials are awaited.
Mantle cell lymphoma (MCL) is an uncommon entity usually affecting older adults and presenting with advanced-stage disease; the prognosis of MCL with CHOP-like regimens is poor, even prompting clinical trials of autologous hematopoietic cell transplantation (AHCT) as upfront treatment of newly diagnosed MCL patients. In this line, the MD Anderson group described a CR rate of 100% as well as prolonged failure-free and overall survival by using the hyperCVAD-methotrexatecytarabine (HCVAD) regimen followed by AHCT in MCL patients less than 66 years. 67 The same group recently reported equivalent results with HCVAD combined with Rituximab instead of AHCT, with a trend for even superior outcome in patients above 65 years old.
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Rituximab in the setting of hematopoietic cell transplantation: in vivo purging and adjuvant treatment
In vivo purging
A major cause of relapse post-autologous hematopoietic cell transplantation (AHCT) is reinfusion of malignant cells with the graft. A reduction in the rate of relapse might be expected by pre-transplant elimination of tumor cells from the graft ('purging') followed by post-transplant consolidation treatment to eradicate minimal residual disease. The ex vivo purging protocols have generally been cumbersome and expensive, thus finding limited application. However, the whole idea of purging seems to have taken new directions with the introduction of Rituximab.
Rituximab has now been evaluated for in vivo purging purposes by several groups with generally successful results. [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] Some common themes emerged from these studies: (1) in vivo purging with Rituximab is superior to currently available ex vivo protocols (evidenced, among other tests, by PCR analyses); (2) the administration of Rituximab pre-transplantation concurrently with the salvage/mobilization regimen does not compromise the harvest of peripheral blood progenitor cells even in heavily pretreated patients; (3) stem cells collected post-Rituximab administration function normally; (4) prompt engraftment occurs in almost all patients; however, some studies report transient neutropenia some time post transplantation that resolves within some months without an increased incidence of infections; as we have recently shown, 79 this complication might in fact be an autoimmune phenomenon arising in the setting of T-large granular lymphocyte (CD3 
Adjuvant therapy to high-dose chemotherapy and autologous hematopoietic cell transplantation
The efficacy and safety of Rituximab has been evaluated in the setting of minimal residual disease burden following highdose therapy and AHCT. Horwitz et al 80 at Stanford reported preliminary results of a trial using Rituximab following peripheral blood AHCT. Thirty-five patients with relapsed or refractory aggressive B cell NHL underwent HCT followed by Rituximab 375 mg/m 2 weekly for 4 doses starting on day 40 and repeated for four more doses starting on day 180. Rituximab infusions were well tolerated with only one grade 3/4 infusion-related toxicity. The unexpected adverse event noted in this trial was delayed neutropenia in more than half the patients (19/35 patients with 46 episodes of grade 3 or 4 neutropenia); all patients recovered from neutropenia without an apparent increased incidence of infections over what is typically seen in AHCT. No patients had evidence of B cell recovery at 12 months. With a median follow-up of 18 months, estimated OS at 24 months was 85% and estimated FFP was 86%, higher than expected with conventional AHCT regimens. Buckstein et al 81 used Rituximab as consolidation therapy post high-dose therapy (CBV) and HCT in 21 patients with relapsed follicular lymphoma; with a median follow-up of almost 2 years, high rates of durable and molecular remissions were demonstrated. The same group applied this protocol in 13 newly diagnosed MCL patients and recently reported encouraging preliminary results. 82 For both the aforementioned and all other similarly conducted studies, longer follow-up times are necessary to determine efficacy, durability of responses and the risk of severe infections.
Rituximab in the management of post-transplant Blymphoproliferative disorders
Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation. The incidence of PTLD is rising as organ transplantation becomes more commonplace. Approximately one-third of PTLD patients will achieve a CR with reduction in their immunosuppression. For those who do not respond, other treatments such as chemotherapy are exceedingly toxic with mortality rates as high as 50%. Most PTLDs are composed of CD20 + B cells; this prompted several trials of Rituximab (usually at a dose of 375 mg/m 2 for 4 weeks) for the treatment of patients with PTLD not responding to reduction in immunosuppression. In the largest series reported to date, 83 a French group presented results of a retrospective analysis of Rituximab administration in 32 patients with PTLD developing after solid organ transplants (26 cases: liver 8, kidney 8, heart 4, lung 3, heart lung 1, kidney-pancreas 1, liver-kidney 1) and HCT (6 cases). The treatment was well tolerated leading to an overall RR of 69% with 20 CRs and two PRs; in solid organ transplant, the RR was 65% while in HCT it was 83% (5 patients achieving a CR). With a median follow-up of 8 months, 24 patients were alive; at publication of the study, of 22 responders 15 were alive with no evidence of disease. Similarly encouraging results have been reported by others; [84] [85] [86] furthermore, there is now evidence to suggest an impact of Rituximab on Epstein-Barr infection that usually underlies PTLD. 87 However, caution is needed as numbers are (unavoidably) small and follow-up is too short to assess durability of responses.
Conjugated anti-CD20 MAbs in lymphoma therapy
Another aspect of MAb therapy that has generated much interest is the use of radioimmunoconjugates, MAbs conjugated to radioactivity-emitting molecules. The advantage of using radioimmunoconjugates is that radiotherapy is targeted to the tumor cells, thereby limiting toxic effects on normal cells; the approach is known as radioimmunotherapy (RIT). Tumor eradication is accomplished by the antibody-mediated effects as well as by the cytotoxic activity of the radiation. Beta particles are tumoricidal over a distance of many adjacent cell diameters and achieve killing of antigen-negative tumor cells that would not be eliminated by the antibody alone ('crossfiring' or 'bystander' effect).
Radionuclides, toxins and prodrug-converting enzymes have all been conjugated to MAbs and are at various stages of development in clinical trials. The most promising results have been seen with RIT for B cell NHL, where there appears to be a synergy between the signalling induced by anti-CD20 and the delivery of beta-radiation, an effect also seen in mouse lymphoma models. 88 High RRs have been seen in both newly diagnosed patients 89 as well as those previously extensively treated with chemotherapy. 90, 91 Trials exploring the use of two radioimmunoconjugates, ie iodine-131 ( 131 I)-tositumomab (Bexxar) and yttrium-90 ( 90 Y)-ibritumomab tiuxetan (Zevalin) will be reviewed here.
Iodine-131 tositumomab
I-tositumomab in low-grade and transformed NHL
A radioimmunoconjugate with promising early data is 131 I-tositumomab (Bexxar). A recent phase II study in patients with refractory low-grade or transformed low-grade B cell NHL demonstrated a RR of 57% with a median duration of 9.9 months. 92 Infusion of 131 I-tositumomab was well tolerated with most of the adverse events occurring during the dosimetric infusion and being mild in severity; principal toxicities were hematologic.
Results of a trial with 131 I-tositumomab in previously untreated patients with follicular lymphoma was presented at the ASCO 2000 Meeting. 93 The results of this trial were impressive, with an overall RR of 97% (CR rate: 76%). With a median follow-up of 16.2 months, the duration of response has not yet been reached. The 131 I-tositumomab was well tolerated. Sixty-two percent of patients developed HAMA, and the majority of them experienced mild serum sickness in about 2 weeks following treatment. Long-term follow-up of this study is needed to fully assess the response with this agent.
The results of a multi-center phase II study with 131 I-tositumomab for NHL patients who progressed after treatment with Rituximab indicated a 57% overall RR with 14% CR rate. 94 Retreatment with 131 
I-tositumomab
Due to the reversibility of myelosuppression, the favorable tumor-to-normal tissue ratios with resultant low radiation dose to normal organs, and the infrequent development of HAMA, it is appealing to consider using 131 I-tositumomab for retreatment in patients who relapse after initial response to this radioimmunoconjugate. In the sole such study presented at the 2001 ASCO meeting, 18 patients with low-grade or transformed low-grade NHL who progressed after responding to 131 I-tositumomab therapy were re-treated with 131 I-tositumomab. 95 All patients had a CR/PR of at least 3 months duration after initial 131 I-tositumomab treatment, with a median time to re-treatment of 20 months. Patients were required to have adequate bone marrow function, Ͻ25% bone marrow involvement with lymphoma and HAMA negativity. Dosing was based on individual patient dosimetry after a pre-treatLeukemia ment infusion of a tracer dose followed by planar imaging. Responses were seen in 12/18 (67%) patients, with six patients (33%) achieving CR. The median duration of response was 10.6 months, which is similar to the median of 13 months response duration following the initial I-tositumomab retreatment were of similar severity to those seen after initial first-line therapy. Three patients (17%) developed myelodysplasia (MDS) 4.5-6.1 years after retreatment with 131 I-tositumomab. Since the natural history of low-grade NHL is characterized by remissions and recurrences after each subsequent treatment, therapy that can be delivered repeatedly during subsequent relapses, without significant loss of efficacy, represents a rather valuable tool in the armamentarium of the available treatments for low-grade NHL.
The incidence of secondary MDS observed in the above study raises significant concerns regarding RIT, and should be evaluated prospectively with care. An overview of seven trials involving 131 I-tositumomab therapy of NHL in 773 patients concerning the incidence of therapy-related MDS/AML (tMDS/tAML) was presented in the 43rd ASH meeting. 96 Overall, 20 patients had developed tMDS/tAML which was confirmed on hematopathology review, representing an annual incidence of 1.45%. Five of these 20 patients had tMDS in their pre-RIT marrow. In 11/12 of these patients bone marrow cytogenetics were available and indicated abnormalities of chromosomes 5 or 7. Eight of the 15 tMDS/tAML cases were from a phase I trial that enrolled 59 heavily pre-treated patients, who had received a median of six cytotoxic regimens prior to 131 I-tositumomab, including alkylating agents, topoisomerase II inhibitors, and radiotherapy. With a median follow-up of 3.2 years for these same heavily pre-treated patients, the annualized incidence was 3.8%. In contrast, there have been no cases of tMDS/tAML in 76 previously untreated patients after a 2.7-year median follow-up. Overall, the incidence rates of tMDS/tAML following targeted systemic radiation with 131 I-tositumomab appear comparable to those reported in the pre-RIT chemotherapy ± radiotherapy era for low-grade NHL. Nevertheless, long-term follow-up data will be required in order to assess delayed hematopoietic stem cell damage and decrease in bone marrow reserve from RIT strategies.
CHOP followed by 131 I-tositumomab
The results of a Southwest Oncology Group (SWOG) phase II trial evaluating CHOP followed by 131 I-tositumomab for the treatment of patients with newly diagnosed follicular lymphoma were presented by Press et al 97 during the 43rd ASH 2001 annual meeting in Orlando, Florida. Ninety-two patients with newly diagnosed follicular lymphomas were treated with CHOP followed by 131 I-tositumomab RIT as consolidation. Seventy-one patients were evaluable for response and 60 were evaluable for toxicity. With regard to efficacy, at the time of the analysis, a 52% CR rate and a 28% PR rate, for an 80% overall RR, were observed on intention-to-treat. Grade 4 toxicities were recorded in 13% of patients, and consisted of neutropenia, thrombocytopenia, and infusion-related anaphylactoid reaction and chest or back pain. These data suggest that sequential therapy with CHOP×6P 
RIT with 131 I-tositumomab as part of the preparative regimen in hematopoietic stem cell transplantation
Patients with aggressive NHL who are a primary induction failure or relapse with chemo-refractory disease have a poor outlook with standard high-dose chemotherapy and AHCT. Investigators from Nebraska conducted a phase I/II trial evaluating the addition of standard dose of 131 I-tositumomab given sequentially with the high-dose BEAM (BCNU, etoposide, Ara-C, and melphalan) transplant regimen followed by AHCT in patients with aggressive NHL and primary induction failure or relapsed chemo-refractory disease. 98 Twenty-three patients with follicular (n = 4), diffuse large cell (n = 14), or MCL (n = 5) received 131 I-tositumomab on an outpatient basis. The patients received a tracer dose of 131 I-tositumomab on day −19 followed by the calculated total body therapy dose (TBD) of 131 Itositumomab on day −12 in four dose cohorts (30 cGy, 45 cGy, 60 cGy and 75 cGy). The BEAM chemotherapy was administered starting on day −6 followed by ASCT. The median time to reach an absolute neutrophil count 500/l was 10 days, median time to platelet transfusion independence was 12 days, and median time to red blood cell transfusion independence was 9 days. There were no treatment-associated deaths. The CR rate was 57% and PR rate of 9% for an overall RR of 66%. With a median follow-up of 12 months (range, 4-28) the estimated 1 year event-free survival was 60% and the estimated OS 78%. The authors concluded that the addition of 131 I-tositumomab at standard doses, which can be delivered on an outpatient basis with the BEAM transplant regimen, is easily administered with no delay in engraftment and looks promising as a synergisitic treatment for refractory aggressive NHL. A phase II trial with 131 I-tositumomab at 75-cGy TBD sequentially with BEAM high-dose chemotherapy followed by ASCT has been initiated.
High-dose 131 I-tositumomab has been applied as a part of the preparative/conditioning regimen in combination with etoposide, cyclophosphamide and ASCT for patients with relapsed or refractory MCL. 99 Fifteen relapsed or refractory MCL patients were treated with high-dose chemo-RIT using 131 I-tositumomab, etoposide, cyclophosphamide and ASCT. A CR rate of 73% was achieved in 13 evaluable patients, a PR rate of 9%, while two patients in remission pre-transplant remained progression free. Almost 50% of patients with PCR+ bone marrow converted to PCR negativity at 1 month post transplant. All 15 patients remained alive without progression with a median follow-up of 12 months from AHCT and 44 months since diagnosis. Toxicities were comparable to standard transplant regimens with a median time of neutrophil count Ͻ500 of 12 days (range, 9-19 days). Therefore, highdose 131 I-tositumomab, etoposide, cyclophosphamide and AHCT may provide a beneficial therapeutic option for relapsed MCL patients that otherwise carry a poor prognosis, although longer follow-up and additional patients will be needed to assess the reproducibility and durability of these findings.
The above two studies, attempting to incorporate high-dose RIT as a part of high-dose chemotherapy preparative regimens with AHCT in relapsed/refractory B cell NHL, indicate that radiolabeled anti-CD20 MAbs may substitute total body irradiation (TBI), an effective cytoreductive modality in hematologic malignancies usually incorporated in conditioning regimens, and deliver more irradiation to disease-involved areas than to normal organs, thus constituting a more effective and less toxic modality to be combined with cytotoxic agents in this setting.
90
Yttrium ibritumomab tiuxetan (Zevalin) 90 Yttrium ibritumomab tiuxetan (Zevalin) is composed of a murine monoclonal antibody, ibritumomab, which targets the CD20 antigen, and the radioisotope 90 Y, which are linked by the bifunctional chelator, tiuxetan.
Phase I-II study of 90 yttrium ibritumomab tiuxetan infusions in an outpatient setting. They were well tolerated with no infusionrelated toxic effects. Adverse effects were primarily hematologic and transient. At the 0.4-mCi/kg dose level, the median nadir values of platelets, absolute granulocytes, and hemoglobin were 50 000/l, 1100/l, and 9.9 g/dl, respectively. Five patients (10%) had platelet nadirs less than 10 000/l, and 27% of patients had absolute granulocyte counts of less than 500/l. The overall RR in the intent-to-treat analysis was 67% (complete RR, 26%). The RR was 82% for low-grade lymphoma and 43% for intermediate-grade lymphoma. Y-ibritumomab tiuxetan evaluated the safety of high-dose chemotherapy with AHCT rescue and demonstrated that these patients could be treated efficiently with this approach despite prior RIT. All but one patient, who died during absolute neutropenia, engrafted and all had mobilized stem cells successfully despite concerns about potential hematopoietic stem cell damage from prior RIT. 103 A total of 349 patients with relapsed/refractory low-grade, follicular, transformed, or intermediate-grade B cell NHL has been treated with 90 Y-ibritumomab tiuxetan (Zevalin) in five clinical trials of RIT. Overall, treatment has been found to be well tolerated, despite the increased risk for toxicity in this population. 104 Moreover, a single case of WM, that had been heavily pretreated with multiple chemotherapy regimens and Rituximab achieving no or minor response, received 90 Y-ibritumomab, which led to a long-lasting CR. 105 
Y-ibritumomab in relapsed NHL
RIT with 90 Y-ibritumomab tiuxetan (Zevalin) as part of the preparative regimen in hematopoietic stem cell transplantation
The first phase I-II study aiming to determine the MTD of absorbed irradiation to critical organs delivered by 90 Y-ibritumomab tiuxetan in combination with standard high-dose BEAM chemotherapy and autologous AHCT was reported in the 43rd ASH meeting. Twelve patients with relapsed or refractory CD20
+ NHL were treated in cohorts of three to six patients at doses calculated to result in increasing irradiation exposure (100, 300 or 500 cGy) to the critical organ (liver, lung or kidney). 106 On day −22, patients received Rituximab 250 mg/m 2 followed by the imaging dose of 111 In-ibritumomab (5 mCi), with immunolocalization studies performed at 0, 4, 24, 72 and 144 h post-Mab injection; dosimetry was performed on day −15. On day −14, Rituximab at 250 mg/m 2 Leukemia followed by 90 Y-ibritumomab at an initial dose calculated to deliver no more than 100 cGy to critical organs was administered. The 90 Y-ibritumomab dose was escalated in cohorts of three patients. High-dose BEAM was administered days −6 to −1 followed on day 0, by infusion of у2.0 × 10 6 CD34 + cells/kg, with G-CSF 5 g/kg beginning on day 0. Three patients had MCL, seven had diffuse aggressive NHL, and two had follicular NHL. Grade III/IV toxicities included fever, infection, hemorrhage, nausea, vomiting, diarrhea, and stomatitis consistent with those seen in patients receiving BEAM alone. Engraftment for granulocytes was seen at a median of 10 days (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and for platelets on day 20 (range, . It was concluded that the addition of a therapeutic dose of 90 Y-ibritumomab to high-dose BEAM chemotherapy is likely to be without serious toxicity, and further phase II evaluation is ongoing.
Comparison between
131
I-tositumomab (Bexxar) and 90 
Yibritumomab tiuxetan (Zevalin)
There are several differences between these two radioimmunoconjugates. Although both 131 I and 90 Y are ␤-emitters,
90
Y emits ␤-particles of higher energy, a longer path length, and a shorter half-life. Radiolabeling of the two MAbs differs substantially; 131 I is attached to the antibody on tyrosine residues and the procedure is easy and widely applicable in contrast to 90 Y which requires a bifunctional chelating agent (tiuxetan; Mx-DTPA) to be first attached to the antibody by specialized radiochemistry methodology, available in specialized laboratories. With respect to in vivo stability, 131 I-labeled antibodies are relatively unstable, as 131 I is easily dettached from the antibody by blood and tissue dehalogenases, while 90 Y is maintained rather stably on the antibody through the chelator, and is only minimally detached by binding to circulating transferrin. Moreover, with respect to bifunctional chelating agents, we have demonstrated in the past that these are potently immunogenic 107, 108 and therefore, care should be taken with monitoring potential immunogenicity of tiuxetan in NHL RIT trials. Because 90 Y is not a ␥-emitter, planar imaging or dosimetric calculations with 90 Y-ibritumomab requires the use of an 111 In conjugate. There are differences in dosing, administration, safety requirements (particular to radioactive iodine), and cost.
131 I-tositumomab and 90 Y-ibritumomab have not been compared directly, and it remains to be determined which radioimmunoconjugate is best for each of the many possible indications. Clinical studies described in the previous sections add to the growing evidence of significant efficacy of RIT in various clinical scenarios.
Pharmacokinetics of the anti-CD20-radiolabeled antibodies depends on a number of patient-specific and disease-specific factors. Because these lead to high variability in the half-life of the drug, dosimetry may be important to ensure the delivery of a prescribed dose of RIT. However, dosimetry has significant practical shortcomings in that it is cumbersome and adds additional costs to therapy. A fixed dosing regimen is clearly not as accurate but might still result in an acceptable safety and efficacy profile. The experience with 90 Y-ibritumomab radioimmunoconjugate, indicates that dosimetry can be omitted safely in the majority of patients. 109 Because the 90 Y isotope used in 90 Y-ibritumomab is a pure ␤-emitter, dosimetry with that agent requires the preparation of an alternative radioimmunoconjugate between anti-CD20 MAb and 111 In to permit ␥-camera imaging.
The present clinical development of 131 Leukemia 90 Y-ibritumomab requires dosimetry-based dosing for 131 I-tositumomab, but accepts fixed dosing (mCi/kg) for 90 Y-ibritumomab without major differences in their toxicity or efficacy profile. Prospective clinical studies are needed to assess which dosing approach is clinically relevant and should be accepted by practicing physicians.
Conclusions
MAb therapy of lymphoma has evolved into a new era where treatment with these agents is currently incorporated with other conventional/standard chemotherapy or high-dose chemotherapy + autologous hematopoietic stem cell transplantation strategies in order to eliminate residual drug-resistant lymphoma sub-clones or sensitize tumor cells to chemotherapy-induced apoptosis and eventually improve treatment results. It remains to be seen whether such approaches, most already noted 12 years ago, 110 will have an impact in the cure rate of patients with NHL. 111 
